<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390532</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0096</org_study_id>
    <secondary_id>2010-A00265-34</secondary_id>
    <nct_id>NCT01390532</nct_id>
  </id_info>
  <brief_title>Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT</brief_title>
  <official_title>Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Cardiac Resynchronization Therapy (CRT) is an established treatment for patients with
      advanced heart failure and left ventricular dyssynchrony (LVD). Too many patients do not
      clinically improve with CRT. New LVD markers other than QRS duration are needed.

      Study objective : feasibility assessment of rest and real-time stress 3D Blood-Pool Gated
      SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®,
      Ceasaria, Israel) to quantify LVD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of
      dobutamine and atropin infusion (&gt;85% PHR).

      Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will
      be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles,
      CA).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular phase standard deviation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular entropy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fraction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minutes walking test</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Left Ventricular Dyssynchrony</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)</intervention_name>
    <description>Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (&gt;85% PHR).
Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic heart failure with LVEF &lt; 35 %, QRS &gt; 120 ms, NYHA III/IV, optimal medical therapy
        for more than one month.

          -  Patient with stable hemodynamic for more than one month,

          -  More than 18-year old man or woman,

          -  Patient having given his free, inform and signed consent,

          -  Patient place setting by the social security system,

        Exclusion Criteria:

          -  Psychiatric disorder

          -  Any contra-indication to Technetium,

          -  Any contra-indication to dobutamin or atropin

          -  Personal or family history of sudden death

          -  Previous severe ventricular arrhythmia

          -  Obstructive cardiomyopathy, severe aortic stenosis,

          -  Pulmonary hypertension,

          -  History of renal, lung, hepatic, cardiac transplantation,

          -  Pregnant or breast-feeding Woman,

          -  Patient who can not conform to the requirements of the protocol,

          -  Patient included in another medical study,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CITRON</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de CLERMONT-FERRAND</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patrick LACARIN</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Left Ventricular Dyssynchrony</keyword>
  <keyword>Gated blood-pool</keyword>
  <keyword>D-SPECT</keyword>
  <keyword>Pharmacological stress</keyword>
  <keyword>NYHA III/IV</keyword>
  <keyword>LVEF &lt; 35 %</keyword>
  <keyword>QRS &gt; 120 ms</keyword>
  <keyword>optimal medical treatment</keyword>
  <keyword>cardiac resynchronization therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

